November 20, 2026
Andamertinib Benzoate Capsules (安比锐®) Companion Diagnostic Kit Receives NMPA Approval

On November 20, 2026, Guangzhou Burning Rock Dx Co., Ltd. (NASDAQ: BNR, Burning Rock) and Beijing Avistone Biotechnology Co., Ltd. (Avistone) jointly announced that the companion diagnostic kit for Andamertinib Benzoate Capsules (安比锐®, Andamertinib), developed through their collaboration, has received approval from China’s National Medical Products Administration (NMPA). The kit is approved for detecting EGFR exon 20 insertion (exon20ins) mutations in patients with non-small cell lung cancer (NSCLC), supporting the identification of eligible patients and informed treatment decisions.


Andamertinib, an EGFR exon 20 insertion (exon20ins) inhibitor independently developed by Avistone Pharmaceutical (Ningbo) Co., Ltd. (Ningbo Avistone), a wholly owned subsidiary of Avistone, received conditional approval from the NMPA on April 30, 2026. It is indicated for adult patients with locally advanced or metastatic NSCLC who have experienced disease progression during or following platinum-based chemotherapy, or who are intolerant to platinum-based chemotherapy, and who have been confirmed by testing to have an exon 20 insertion mutation in EGFR.


On November 14, 2026, Andamertinib was included for the first time in China’s 2026 National Reimbursement Drug List (NRDL), which will take effect on January 1, 2027, potentially improving access to and affordability of this innovative treatment.

Learn More
October 27, 2026
Burning Rock Presents STELLA Clinical Validation at ESMO 2026, Exploring an Adjunctive Approach to Differentiating Benign and Malignant Breast Lesions
Learn More
October 10, 2026
Burning Rock’s OncoCompass® Target CDx Kit Enters NMPA Priority Approval Procedure
Learn More
September 16, 2026
Burning Rock Presents Three Studies at WCLC 2026, Exploring Precision Lung Cancer Care Across Disease Biology, Treatment Response and Molecular Testing
Learn More
September 11, 2026
Burning Rock Reports Second Quarter 2026 Financial Results: Total Revenue Reaches RMB134.7 Million
Learn More
September 09, 2026
Burning Rock's Second WES-Based Personalized MRD Kit Enters NMPA Special Review Procedure for Innovative Medical Devices
Learn More
August 25, 2026
Burning Rock’s WES-Based Personalized MRD Kit Enters NMPA Special Review Procedure for Innovative Medical Devices
Learn More
July 17, 2026
Burning Rock Biotech and Myriad Genetics Announce Global Strategic Technology Licensing Partnership to Expand NGS-based HRD Testing Worldwide
Learn More
June 09, 2026
Burning Rock Reports Unaudited First Quarter 2026 Financial Results: Revenue Reaches US$ 15.6 million with Growing In-Hospital Sales
Learn More
February 03, 2026
Burning Rock & CTONG Lab Achieves Full Marks in Four International EQA Programs by NCCL, CAP, and EMQN
Learn More
1 2 3 4
Contact Our Experts
We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."